Grandfield & Dodd’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22.8M Sell
163,600
-8,425
-5% -$1.18M 1.29% 29
2025
Q4
$21.1M Sell
172,025
-28,306
-14% -$3.44M 1.2% 32
2025
Q3
$22.2M Sell
200,331
-20,655
-9% -$2.35M 1.26% 28
2025
Q2
$24.5M Sell
220,986
-60,746
-22% -$6.46M 1.43% 24
2025
Q1
$31.6M Sell
281,732
-2,030
-0.7% -$209K 1.96% 17
2024
Q4
$26.2M Sell
283,762
-1,147
-0.4% -$103K 1.62% 23
2024
Q3
$23.9M Buy
284,909
+1,945
+0.7% +$148K 1.42% 26
2024
Q2
$19.4M Buy
282,964
+3,230
+1% +$216K 1.23% 30
2024
Q1
$20.5M Sell
279,734
-1,246
-0.4% -$95.8K 1.29% 30
2023
Q4
$22.8M Sell
280,980
-97
-0% -$7.55K 1.57% 25
2023
Q3
$21.1M Buy
281,077
+5,566
+2% +$428K 1.55% 24
2023
Q2
$21.2M Sell
275,511
-2,826
-1% -$225K 1.48% 24
2023
Q1
$23.1M Buy
278,337
+2,121
+0.8% +$176K 1.61% 24
2022
Q4
$23.7M Buy
276,216
+3,968
+1% +$314K 1.74% 23
2022
Q3
$16.8M Buy
272,248
+8,485
+3% +$535K 1.37% 34
2022
Q2
$16.3M Buy
263,763
+11,921
+5% +$738K 1.28% 36
2022
Q1
$15M Buy
251,842
+8,546
+4% +$546K 1.02% 42
2021
Q4
$17.7M Buy
243,296
+7,042
+3% +$485K 1.14% 36
2021
Q3
$16.5M Buy
236,254
+13,290
+6% +$934K 1.15% 36
2021
Q2
$15.3M Buy
222,964
+20,344
+10% +$1.36M 1.06% 39
2021
Q1
$13.1M Buy
202,620
+16,640
+9% +$1.07M 0.98% 41
2020
Q4
$10.8M Buy
185,980
+3,370
+2% +$203K 0.85% 42
2020
Q3
$11.5M Buy
182,610
+3,973
+2% +$276K 1.04% 38
2020
Q2
$13.7M Sell
178,637
-1,008
-0.6% -$77.3K 1.33% 31
2020
Q1
$13.4M Buy
179,645
+5,581
+3% +$386K 1.58% 22
2019
Q4
$11.3M Buy
174,064
+4,475
+3% +$291K 1.03% 40
2019
Q3
$10.7M Buy
169,589
+3,875
+2% +$253K 1.06% 40
2019
Q2
$11.2M Buy
165,714
+8,314
+5% +$547K 1.11% 37
2019
Q1
$10.2M Buy
157,400
+5,970
+4% +$397K 1.07% 38
2018
Q4
$9.47M Sell
151,430
-605
-0.4% -$42.3K 1.12% 37
2018
Q3
$11.7M Buy
152,035
+5,430
+4% +$410K 1.21% 33
2018
Q2
$10.4M Buy
146,605
+7,670
+6% +$542K 1.14% 38
2018
Q1
$10.5M Buy
138,935
+2,967
+2% +$236K 1.17% 37
2017
Q4
$9.74M Buy
135,968
+7,898
+6% +$600K 1.04% 43
2017
Q3
$10.4M Buy
128,070
+26,167
+26% +$2M 1.16% 39
2017
Q2
$7.21M Buy
101,903
+54,321
+114% +$3.61M 0.85% 43
2017
Q1
$3.23M Buy
47,582
+30,355
+176% +$2.13M 0.4% 61
2016
Q4
$1.23M Buy
17,227
+8,584
+99% +$638K 0.16% 81
2016
Q3
$684K Buy
8,643
+82
+1% +$6.66K 0.09% 103
2016
Q2
$714K Buy
8,561
+675
+9% +$59.9K 0.1% 99
2016
Q1
$724K Buy
7,886
+167
+2% +$15.1K 0.1% 90
2015
Q4
$781K Sell
7,719
-46
-0.6% -$4.79K 0.12% 90
2015
Q3
$762K Buy
7,765
+1,249
+19% +$139K 0.13% 89
2015
Q2
$763K Sell
6,516
-2,063
-24% -$225K 0.12% 91
2015
Q1
$842K Hold
8,579
0.13% 88
2014
Q4
$809K Sell
8,579
-3,604
-30% -$373K 0.13% 88
2014
Q3
$1.3M Buy
12,183
+264
+2% +$25.9K 0.2% 79
2014
Q2
$988K Hold
11,919
0.15% 94
2014
Q1
$845K Sell
11,919
-520
-4% -$40.8K 0.13% 96
2013
Q4
$934K Buy
12,439
+797
+7% +$55.5K 0.15% 92
2013
Q3
$732K Hold
11,642
0.13% 100
2013
Q2
$597K Buy
+11,642
New +$607K 0.11% 107

Other funds holding GILD

Grandfield & Dodd's GILD Position: Q1 2026 in Review

Grandfield & Dodd reduced its Gilead Sciences (GILD) stake by 4.9% in Q1 2026, selling an estimated $1.18M and leaving 163,600 shares worth $22.8M. The position accounts for 1.29% of the portfolio, ranked #29.

Grandfield & Dodd first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $31.6M in Q1 2025. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Grandfield & Dodd held 163,600 shares of Gilead Sciences worth $22.8M as of Q1 2026.
  • Grandfield & Dodd sold 8,425 Gilead Sciences shares in Q1 2026, an estimated $1.18M.
  • Gilead Sciences made up 1.29% of Grandfield & Dodd's portfolio in Q1 2026, its #29 holding.
  • Grandfield & Dodd first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Grandfield & Dodd's Gilead Sciences position peaked at $31.6M in Q1 2025.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.